Incyte and Novartis Resolve Five-Year Royalties Dispute with $280 Million Settlement

In a recent SEC filing, Incyte Corporation announced the resolution of a royalties dispute with Novartis involving the drug Jakafi. This settlement, amounting to $280 million, covers roughly five years of contested royalty payments. The Delaware-based Incyte was represented by legal firms Quinn Emanuel Urquhart & Sullivan and Paul Hastings throughout the proceedings.